SLC22A3 and acute myeloid leukemia: Kaplan–Meier analysis showed that high expression of SLC22A3 predicted longer overall survival (OS) and disease-free survival (DFS) in both non-acute promyelocytic leukemia (APL) AML (non-APL AML) (P = 0.008 and 0.002) and cytogenetically normal AML (CN-AML) patients (P = 0.006 and 0.005; Fig. 1E).